Genomic stability of self-inactivating rabies.

genetics genomics mouse neural circuits neuronal tracing neuroscience rabies viral vector

Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
03 Nov 2023
Historique:
received: 14 09 2022
accepted: 02 11 2023
medline: 24 11 2023
pubmed: 3 11 2023
entrez: 3 11 2023
Statut: epublish

Résumé

Transsynaptic viral vectors provide means to gain genetic access to neurons based on synaptic connectivity and are essential tools for the dissection of neural circuit function. Among them, the retrograde monosynaptic ΔG-Rabies has been widely used in neuroscience research. A recently developed engineered version of the ΔG-Rabies, the non-toxic self-inactivating (SiR) virus, allows the long term genetic manipulation of neural circuits. However, the high mutational rate of the rabies virus poses a risk that mutations targeting the key genetic regulatory element in the SiR genome could emerge and revert it to a canonical ΔG-Rabies. Such revertant mutations have recently been identified in a SiR batch. To address the origin, incidence and relevance of these mutations, we investigated the genomic stability of SiR in vitro and in vivo. We found that "revertant" mutations are rare and accumulate only when SiR is extensively amplified in vitro, particularly in suboptimal production cell lines that have insufficient levels of TEV protease activity. Moreover, we confirmed that SiR-CRE, unlike canonical ΔG-Rab-CRE or revertant-SiR-CRE, is non-toxic and that revertant mutations do not emerge in vivo during long-term experiments.

Identifiants

pubmed: 37921437
doi: 10.7554/eLife.83459
pii: 83459
pmc: PMC10666929
doi:
pii:

Banques de données

SRA
['PRJNA888353']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Medical Research Council
ID : MRC-UP_1201/2
Pays : United Kingdom
Organisme : European Research Council
ID : STG-677029
Pays : International

Informations de copyright

© 2023, Ciabatti et al.

Déclaration de conflit d'intérêts

EC The SiR technology is patented by the UK Research and Innovation (WO2018203049A1), AG, Dd, HL, FM, MT No competing interests declared

Références

Neuron. 2010 Nov 4;68(3):456-72
pubmed: 21040847
J Gene Med. 2004 Feb;6 Suppl 1:S212-22
pubmed: 14978764
J Neurosci. 2015 Jun 17;35(24):8979-85
pubmed: 26085623
Nat Methods. 2007 Jan;4(1):47-9
pubmed: 17179932
Neuron. 2016 Feb 17;89(4):711-24
pubmed: 26804990
BMC Genomics. 2012 Aug 05;13:375
pubmed: 22863213
Nat Neurosci. 2017 Dec;20(12):1796-1806
pubmed: 29184208
Proc Natl Acad Sci U S A. 2023 Feb 14;120(7):e2023481120
pubmed: 37053554
Nat Neurosci. 2016 Feb;19(2):198-205
pubmed: 26814589
Nature. 2018 Apr;556(7701):326-331
pubmed: 29643503
Neuron. 2011 Jul 14;71(1):9-34
pubmed: 21745635
Neuron. 2011 Aug 25;71(4):617-31
pubmed: 21867879
Nat Biotechnol. 2016 Aug;34(8):857-62
pubmed: 27347754
Nat Neurosci. 2018 Apr;21(4):638-646
pubmed: 29507411
Nature. 2017 Feb 2;542(7639):96-100
pubmed: 28117439
Elife. 2022 Aug 30;11:
pubmed: 36040301
Neuron. 2016 Oct 19;92(2):372-382
pubmed: 27720486
J Virol. 1977 Feb;21(2):626-35
pubmed: 833940
Cell. 2017 Jul 13;170(2):382-392.e14
pubmed: 28689641
Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13910-3
pubmed: 10570172
Nature. 2017 Nov 8;551(7679):232-236
pubmed: 29120427
Nat Neurosci. 2017 Aug;20(8):1172-1179
pubmed: 28671695
Neurosci Bull. 2020 Mar;36(3):202-216
pubmed: 31444652
Nature. 2018 Sep;561(7723):349-354
pubmed: 30158697
NAR Genom Bioinform. 2020 May 25;2(2):lqaa037
pubmed: 33575591
Curr Opin Neurobiol. 2008 Dec;18(6):617-23
pubmed: 19349161
Science. 2019 Aug 16;365(6454):699-704
pubmed: 31371562
Cell. 2010 Aug 20;142(4):637-46
pubmed: 20723762
Genome Res. 2017 Mar;27(3):491-499
pubmed: 28100584
Nat Methods. 2023 Apr;20(4):580-589
pubmed: 36864202
Nature. 2011 Oct 19;479(7371):61-6
pubmed: 22012263
J Virol. 2010 Oct;84(19):9733-48
pubmed: 20660197
Nat Methods. 2019 Jul;16(7):649-657
pubmed: 31209382
Nat Neurosci. 2016 Aug 26;19(9):1142-53
pubmed: 27571193
Genomics Proteomics Bioinformatics. 2015 Oct;13(5):278-89
pubmed: 26542840
Genome Biol. 2019 Jan 8;20(1):8
pubmed: 30621750
Neuron. 2007 Mar 1;53(5):639-47
pubmed: 17329205
Nat Neurosci. 2005 Nov;8(11):1491-3
pubmed: 16205719

Auteurs

Ernesto Ciabatti (E)

MRC Laboratory of Molecular Biology, Cambridge, United Kingdom.

Ana González-Rueda (A)

MRC Laboratory of Molecular Biology, Cambridge, United Kingdom.

Daniel de Malmazet (D)

MRC Laboratory of Molecular Biology, Cambridge, United Kingdom.

Hassal Lee (H)

MRC Laboratory of Molecular Biology, Cambridge, United Kingdom.

Fabio Morgese (F)

MRC Laboratory of Molecular Biology, Cambridge, United Kingdom.

Marco Tripodi (M)

MRC Laboratory of Molecular Biology, Cambridge, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH